{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:25:40Z","timestamp":1778858740770,"version":"3.51.4"},"reference-count":51,"publisher":"Zhejiang University Press","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1631\/jzus.b2200016","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T11:02:30Z","timestamp":1660993350000},"page":"666-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression","\u7ec4\u86cb\u767d\u53bb\u4e59\u9170\u5316\u9176(HDAC)\u6291\u5236\u5242\u897f\u8fbe\u672c\u80fa\u8054\u5408\u7ef4\u5948\u6258\u514b\u901a\u8fc7\u4e0b\u8c03MYC\u3001BCL2\u548cTP53\u7684\u8868\u8fbe\u534f\u540c\u6291\u5236\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u7684\u751f\u957f"],"prefix":"10.1631","volume":"23","author":[{"given":"Cancan","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-8782","authenticated-orcid":false,"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"issue":"3","key":"629_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/0008-5472.CAN-15-1751","volume":"76","author":"CM Adams","year":"2016","unstructured":"Adams CM, Hiebert SW, Eischen CM, 2016. Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res, 76(3): 736\u2013748. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1751","journal-title":"Cancer Res"},{"issue":"5","key":"629_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri A, Wolf E, Eilers M, 2020. Target gene-independent functions of MYC oncoproteins. Nat Rev Mol Cell Biol, 21(5):255\u2013267. https:\/\/doi.org\/10.1038\/s41580-020-0215-2","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"629_CR3","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.3390\/cancers12123553","volume":"12","author":"MR Berendsen","year":"2020","unstructured":"Berendsen MR, Stevens WBC, van den Brand M, et al., 2020. Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance. Cancers, 12(12):3553. https:\/\/doi.org\/10.3390\/cancers12123553","journal-title":"Cancers"},{"issue":"5","key":"629_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","volume":"61","author":"PD Bhola","year":"2016","unstructured":"Bhola PD, Letai A, 2016. Mitochondria\u2014judges and executioners of cell death sentences. Mol Cell, 61(5):695\u2013704. https:\/\/doi.org\/10.1016\/j.molcel.2016.02.019","journal-title":"Mol Cell"},{"issue":"14","key":"629_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2016-08-736066","volume":"130","author":"M Bobrowicz","year":"2017","unstructured":"Bobrowicz M, Dwojak M, Pyrzynska B, et al., 2017. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 130(14): 1628\u20131638. https:\/\/doi.org\/10.1182\/blood-2016-08-736066","journal-title":"Blood"},{"issue":"7","key":"629_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/17474086.2016.1182858","volume":"9","author":"M Burotto","year":"2016","unstructured":"Burotto M, Berkovits A, Dunleavy K, 2016. Double hit lymphoma: from biology to therapeutic implications. Exp Rev Hematol, 9(7):669\u2013678. https:\/\/doi.org\/10.1080\/17474086.2016.1182858","journal-title":"Exp Rev Hematol"},{"key":"629_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/OTT.S93528","volume":"10","author":"TS Chan","year":"2017","unstructured":"Chan TS, Tse E, Kwong YL, 2017. Chidamide in the treatment of peripheral T-cell lymphoma. OncoTargets Ther, 10:347\u2013352. https:\/\/doi.org\/10.2147\/ott.S93528","journal-title":"OncoTargets Ther"},{"issue":"9","key":"629_CR8","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","volume":"11","author":"K Chen","year":"2020","unstructured":"Chen K, Yang QY, Zha J, et al., 2020. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis, 11(9):778. https:\/\/doi.org\/10.1038\/s41419-020-02972-2","journal-title":"Cell Death Dis"},{"issue":"2","key":"629_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC, 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res, 70(2):440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"issue":"20","key":"629_CR10","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-16-1248","volume":"76","author":"CM Croce","year":"2016","unstructured":"Croce CM, Reed JC, 2016. Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res, 76(20):5914\u20135920. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1248","journal-title":"Cancer Res"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, O\u2019Grady S, Tang MH, et al., 2021. MYC as a target for cancer treatment. Cancer Treat Rev, 94:102154. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102154","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"629_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/neuonc\/noaa191","volume":"23","author":"J Ecker","year":"2021","unstructured":"Ecker J, Thatikonda V, Sigismondo G, et al., 2021. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro Oncol, 23(2):226\u2013239. https:\/\/doi.org\/10.1093\/neuonc\/noaa191","journal-title":"Neuro Oncol"},{"issue":"5","key":"629_CR13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW, 2017. How I treat double-hit lymphoma. Blood, 130(5):590\u2013596. https:\/\/doi.org\/10.1182\/blood-2017-04-737320","journal-title":"Blood"},{"issue":"7","key":"629_CR14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ijms20071601","volume":"20","author":"P Gong","year":"2019","unstructured":"Gong P, Wang YT, Jing YK, 2019. Apoptosis induction by histone deacetylase inhibitors in cancer cells: role of Ku70. Int J Mol Sci, 20(7):1601. https:\/\/doi.org\/10.3390\/ijms20071601","journal-title":"Int J Mol Sci"},{"issue":"1","key":"629_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","volume":"11","author":"XW Guan","year":"2020","unstructured":"Guan XW, Wang HQ, Ban WW, et al., 2020. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis, 11(1):20. https:\/\/doi.org\/10.1038\/s41419-019-2210-0","journal-title":"Cell Death Dis"},{"issue":"6","key":"629_CR16","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/cancers13061292","volume":"13","author":"S Hafezi","year":"2021","unstructured":"Hafezi S, Rahmani M, 2021. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers, 13(6): 1292. https:\/\/doi.org\/10.3390\/cancers13061292","journal-title":"Cancers"},{"issue":"5","key":"629_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","volume":"5","author":"AN Hata","year":"2015","unstructured":"Hata AN, Engelman JA, Faber AC, 2015. The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov, 5(5):475\u2013487. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0011","journal-title":"Cancer Discov"},{"issue":"11","key":"629_CR18","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2012-08-450916","volume":"121","author":"MR Heideman","year":"2013","unstructured":"Heideman MR, Wilting RH, Yanover E, et al., 2013. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood, 121(11):2038\u20132050. https:\/\/doi.org\/10.1182\/blood-2012-08-450916","journal-title":"Blood"},{"issue":"1","key":"629_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1631\/jzus.B1900351","volume":"21","author":"H Huang","year":"2020","unstructured":"Huang H, Wu HW, Hu YX, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory\/relapsed multiple myeloma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):29\u201341. https:\/\/doi.org\/10.1631\/jzus.B1900351","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"issue":"11","key":"629_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, et al., 2020. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis, 11(11):941. https:\/\/doi.org\/10.1038\/s41419-020-03144-y","journal-title":"Cell Death Dis"},{"key":"629_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.canlet.2020.05.008","volume":"486","author":"S Laszig","year":"2020","unstructured":"Laszig S, Boedicker C, Weiser T, et al., 2020. The novel dual BET\/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells. Cancer Lett, 486:46\u201357. https:\/\/doi.org\/10.1016\/j.canlet.2020.05.008","journal-title":"Cancer Lett"},{"issue":"1","key":"629_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"SY Li","year":"2018","unstructured":"Li SY, Young KH, Medeiros LJ, 2018. Diffuse large B-cell lymphoma. Pathology, 50(1):74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"629_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","volume":"12","author":"WP Li","year":"2019","unstructured":"Li WP, Gupta SK, Han WG, et al., 2019. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol, 12:73. https:\/\/doi.org\/10.1186\/s13045-019-0761-2","journal-title":"J Hematol Oncol"},{"key":"629_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2017.04.037","volume":"90","author":"X Li","year":"2017","unstructured":"Li X, Yan X, Guo WJ, et al., 2017. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother, 90:699\u2013704. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.037","journal-title":"Biomed Pharmacother"},{"key":"629_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/B978-0-12-394387-3.00005-7","volume":"116","author":"GM Matthews","year":"2012","unstructured":"Matthews GM, Newbold A, Johnstone RW, 2012. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res, 116:165\u2013197. https:\/\/doi.org\/10.1016\/B978-0-12-394387-3.00005-7","journal-title":"Adv Cancer Res"},{"issue":"9","key":"629_CR26","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin RD, Assouline S, Alcaide M, et al., 2016. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res, 22(9):2290\u20132300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2123","journal-title":"Clin Cancer Res"},{"issue":"10","key":"629_CR27","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3390\/ijms20102415","volume":"20","author":"M Mrakovcic","year":"2019","unstructured":"Mrakovcic M, Kleinheinz J, Fr\u00f6hlich LF, 2019. p53 at the crossroads between different types of HDAC inhibitormediated cancer cell death. Int J Mol Sci, 20(10):2415. https:\/\/doi.org\/10.3390\/ijms20102415","journal-title":"Int J Mol Sci"},{"issue":"5","key":"629_CR28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.celrep.2014.07.057","volume":"8","author":"N Muthalagu","year":"2014","unstructured":"Muthalagu N, Junttila MR, Wiese KE, et al., 2014. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep, 8(5):1347\u20131353. https:\/\/doi.org\/10.1016\/j.celrep.2014.07.057","journal-title":"Cell Rep"},{"issue":"10","key":"629_CR29","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","volume":"23","author":"A Nebbioso","year":"2017","unstructured":"Nebbioso A, Carafa V, Conte M, et al., 2017. c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. Clin Cancer Res, 23(10):2542\u20132555. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2388","journal-title":"Clin Cancer Res"},{"issue":"4","key":"629_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","volume":"69","author":"ZQ Ning","year":"2012","unstructured":"Ning ZQ, Li ZB, Newman MJ, et al., 2012. Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol, 69(4):901\u2013909. https:\/\/doi.org\/10.1007\/s00280-011-1766-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"629_CR31","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"XJ Niu","year":"2016","unstructured":"Niu XJ, Zhao JY, Ma J, et al., 2016. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res, 22(17):4440\u20134451. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3057","journal-title":"Clin Cancer Res"},{"issue":"12","key":"629_CR32","doi-asserted-by":"publisher","first-page":"djw257","DOI":"10.1093\/jnci\/djw257","volume":"108","author":"GS Nowakowski","year":"2016","unstructured":"Nowakowski GS, Blum KA, Kahl BS, et al., 2016. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. JNCI, 108(12):djw257. https:\/\/doi.org\/10.1093\/jnci\/djw257","journal-title":"JNCI"},{"key":"629_CR33","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1038\/ncomms7921","volume":"6","author":"H Pan","year":"2015","unstructured":"Pan H, Jiang YW, Boi M, et al., 2015. Epigenomic evolution in diffuse large B-cell lymphomas. Nat Commun, 6:6921. https:\/\/doi.org\/10.1038\/ncomms7921","journal-title":"Nat Commun"},{"issue":"1","key":"629_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","volume":"30","author":"A Patriarca","year":"2021","unstructured":"Patriarca A, Gaidano G, 2021. Investigational drugs for the treatment of diffuse large B-cell lymphoma. Exp Opin Invest Drugs, 30(1):25\u201338. https:\/\/doi.org\/10.1080\/13543784.2021.1855140","journal-title":"Exp Opin Invest Drugs"},{"key":"629_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Neto JVP, et al., 2018. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol, 11:65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2","journal-title":"J Hematol Oncol"},{"issue":"24","key":"629_CR36","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM, 2018. Double hit and double expressors in lymphoma: definition and treatment. Cancer, 124(24): 4622\u20134632. https:\/\/doi.org\/10.1002\/cncr.31646","journal-title":"Cancer"},{"issue":"3","key":"629_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodr\u00edguez-Paredes","year":"2011","unstructured":"Rodr\u00edguez-Paredes M, Esteller M, 2011. Cancer epigenetics reaches mainstream oncology. Nat Med, 17(3):330\u2013339. https:\/\/doi.org\/10.1038\/nm.2305","journal-title":"Nat Med"},{"issue":"2","key":"629_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","volume":"31","author":"A Rosenthal","year":"2017","unstructured":"Rosenthal A, Younes A, 2017. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev, 31(2):37\u201342. https:\/\/doi.org\/10.1016\/j.blre.2016.09.004","journal-title":"Blood Rev"},{"issue":"17","key":"629_CR39","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2012-10-461988","volume":"121","author":"F Santoro","year":"2013","unstructured":"Santoro F, Botrugno OA, Dal Zuffo R, et al., 2013. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood, 121(17):3459\u20133468. https:\/\/doi.org\/10.1182\/blood-2012-10-461988","journal-title":"Blood"},{"issue":"15","key":"629_CR40","doi-asserted-by":"publisher","first-page":"E555","DOI":"10.1016\/S1470-2045(15)00005-4","volume":"16","author":"C Sarkozy","year":"2015","unstructured":"Sarkozy C, Traverse-Glehen A, Coiffier B, 2015. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol, 16(15):E555\u2013E567. https:\/\/doi.org\/10.1016\/s1470-2045(15)00005-4","journal-title":"Lancet Oncol"},{"issue":"8","key":"629_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","volume":"16","author":"D Sermer","year":"2019","unstructured":"Sermer D, Pasqualucci L, Wendel HG, et al., 2019. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol, 16(8):494\u2013507. https:\/\/doi.org\/10.1038\/s41571-019-0190-8","journal-title":"Nat Rev Clin Oncol"},{"key":"629_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"YK Shi","year":"2017","unstructured":"Shi YK, Jia B, Xu W, et al., 2017. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol, 10:69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6","journal-title":"J Hematol Oncol"},{"issue":"10","key":"629_CR43","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/leu.2010.157","volume":"24","author":"R Shimizu","year":"2010","unstructured":"Shimizu R, Kikuchi J, Wada T, et al., 2010. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia, 24(10): 1760\u20131768. https:\/\/doi.org\/10.1038\/leu.2010.157","journal-title":"Leukemia"},{"issue":"2","key":"629_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, et al., 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med, 19(2): 202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"629_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cbpa.2019.03.002","volume":"50","author":"G Stazi","year":"2019","unstructured":"Stazi G, Fioravanti R, Mai A, et al., 2019. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Curr Opin Chem Biol, 50:89\u2013100. https:\/\/doi.org\/10.1016\/j.cbpa.2019.03.002","journal-title":"Curr Opin Chem Biol"},{"issue":"20","key":"629_CR46","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al., 2016. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"12","key":"629_CR47","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, Cory S, 2013. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Mycdriven mouse lymphomas without provoking thrombocytopenia. Blood, 121(12):2285\u20132288. https:\/\/doi.org\/10.1182\/blood-2013-01-475855","journal-title":"Blood"},{"key":"629_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J, 2020. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer, 19:5. https:\/\/doi.org\/10.1186\/s12943-019-1127-7","journal-title":"Mol Cancer"},{"issue":"7","key":"629_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"XG Wang","year":"2020","unstructured":"Wang XG, Waschke BC, Woolaver RA, et al., 2020. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell, 11(7):472\u2013482. https:\/\/doi.org\/10.1007\/s13238-020-00694-x","journal-title":"Protein Cell"},{"issue":"3","key":"629_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1358\/dot.2017.53.3.2595452","volume":"53","author":"Y Xu","year":"2017","unstructured":"Xu Y, Zhang P, Liu Y, 2017. Chidamide tablets: HDAC inhibition to treat lymphoma. Drugs Today, 53(3): 167\u2013176. https:\/\/doi.org\/10.1358\/dot.2017.53.3.2595452","journal-title":"Drugs Today"},{"issue":"1","key":"629_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3892\/ol.2019.10301","volume":"18","author":"XG Yuan","year":"2019","unstructured":"Yuan XG, Huang YR, Yu T, et al., 2019. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett, 18(1):411\u2013419. https:\/\/doi.org\/10.3892\/ol.2019.10301","journal-title":"Oncol Lett"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2200016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2200016\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2200016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T12:03:18Z","timestamp":1660996998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2200016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2200016","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}